For whom the bell tolls at Prima Biomed - CVac ovarian cancer vaccine

For whom the bell tolls at Prima Biomed

"Prima is developing a treatment for ovarian cancer and, at 22¢, its market capitalisation is $256 million. This is hefty for a company that is not forecast to make a profit for at least another four years (if it ever does)."

"The clinical results Prima Biomed has come up with so far do not seem to support its share price rise from 2¢ or so in early 2009, to peak at 39¢ this time last year. The full results of its preliminary (phase two) are due out in the next few months, but what we know so far is that the data from 21 patients ''has not demonstrated statistically significant results'', in the words of a report by Nomura Equity Research."

Read more: http://www.smh.com.au/business/for-whom-the-bell-tolls-at-prima-biomed-20120422-1xf1f.html#ixzz1sonQHSR0

How long before CVac, a new treatment for ovarian cancer, is available in the UK? – Telegraph Blogs

"Since my blog post about the Stage 3 trial of CVac – a new treatment for ovarian cancer – I have been in contact with Dr Neil Frazer, who is heading this research for the Australian company Prima Biomed. He has answered my questions about the treatment, clarified the methodology and explained about Prima Biodmed's medical facility in Dubai where CVac will be supplied......

Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial -- SYDNEY, Feb. 18, 2011 /PRNewswire/ --

"......The trial will be conducted on 750 patients in a double blind placebo controlled study randomized 1:1 of CVac vs. Standard of Care (currently there is no approved maintenance therapy for ovarian cancer), across multiple sites in Europe, the US and Australia....."

FDA Approval For Dendreon Provenge Immunotherapy Vaccine - pharma news/Australia "CVac"

"Dendreon is using cancer immunotherapies that use the patient's own immune system to treat cancer and the approval of Provenge represents a scientific and clinical advancement for the treatment of prostate cancer.

Prima BioMed, an Australian biotechnology firm focused on cancer immunotherapy, is using the technology to develop its CVac immunotherapy cancer vaccine for the treatment of ovarian cancer."